Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

By

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma

Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma

By

A review published in Blood highlights new approaches that are being investigated to treat PCNSL based on the mutational landscape and signaling pathways that are extant in the disease.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma

Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma

By

A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

By

Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

By

Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator's choice chemotherapy of CHOP, CVP, or bendamustine.

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

By

Moffitt Cancer Center investigators believe allo-HCT may actually be "curative" for patients with a certain type of lymphoma.

Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Diffuse Large B-Cell Lymphoma

Access detailed treatment regimens for diffuse large B-cell lymphoma, such as R-CHOP with RT and radiotherapy.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

By

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

By

Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).

Long-Term Follow-Up Results of ZUMA-1 Trial

Long-Term Follow-Up Results of ZUMA-1 Trial

Frederick Locke, MD, discusses his research at the ASCO 2018 meeting.

Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma Treatment Regimens

View treatment regimens for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, including combination therapies with bortezomib and more.

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

By

Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.

Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma

Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma

By

Although the findings need to be tested further in clinical trials, this could lead to new targeted therapies with fewer toxicities for patients.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

By

Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

By

Rituximab, gemcitabine, plus oxaliplatin has shown high efficacy with low toxicity among elderly patients with relapsed/refractory diffuse large b-cell lymphoma in previous studies.

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

By

The FDA based its approval on results of the single-arm phase 2 JULIET clinical trial.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Extranodal NK/T-cell Lymphoma

Get current treatment regimens for extranodal NK/T-cell lymphoma, which details options such as radiotherapy plus DeVic and SMILE + radiotherapy.

Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenström Macroglobulinemia

Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenström Macroglobulinemia

By

The median progression-free survival was not reached after a median follow-up of 22 months.

Hodgkin Lymphoma Treatment Regimens

Find comprehensive treatment regimens for Hodgkin lymphoma, including therapies such as ABVD + involved-field radiotherapy and more.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs